Literature DB >> 28539449

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Wen Shi Lee1, Anne B Kristensen1, Thomas A Rasmussen2, Martin Tolstrup2, Lars Østergaard2, Ole S Søgaard2, Bruce D Wines3,4,5, P Mark Hogarth3,4,5, Arnold Reynaldi6, Miles P Davenport6, Sean Emery6,7, Janaki Amin6, David A Cooper6, Virginia L Kan8, Julie Fox9, Henning Gruell10, Matthew S Parsons1, Stephen J Kent11,12,13.   

Abstract

There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency. A potential barrier is that HIV-1-specific ADCC antibodies decline in patients on long-term antiretroviral therapy (ART) and may not be sufficient to eliminate reactivated latently infected cells. It is not known whether reactivation from latency with latency-reversing agents (LRAs) could provide sufficient antigenic stimulus to boost HIV-1-specific ADCC. We found that treatment with the LRA panobinostat or a short analytical treatment interruption (ATI), 21 to 59 days, was not sufficient to stimulate an increase in ADCC-competent antibodies, despite viral rebound in all subjects who underwent the short ATI. In contrast, a longer ATI, 2 to 12 months, among subjects enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) trial robustly boosted HIV-1 gp120-specific Fc receptor-binding antibodies and ADCC against HIV-1-infected cells in vitro These results show that there is a lag between viral recrudescence and the boosting of ADCC antibodies, which has implications for strategies toward eliminating latently infected cells.IMPORTANCE The "shock and kill" HIV-1 cure strategy aims to reactivate HIV-1 expression in latently infected cells and subsequently eliminate the reactivated cells through immune-mediated killing. Several latency reversing agents (LRAs) have been examined in vivo, but LRAs alone have not been able to achieve HIV-1 remission and prevent viral rebound following analytical treatment interruption (ATI). In this study, we examined whether LRA treatment or ATI can provide sufficient antigenic stimulus to boost HIV-1-specific functional antibodies that can eliminate HIV-1-infected cells. Our study has implications for the antigenic stimulus required for antilatency strategies and/or therapeutic vaccines to boost functional antibodies and assist in eliminating the latent reservoir.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  ADCC; HIV-1 cure; SMART trial; analytical treatment interruption; latency; latency-reversing agent; panobinostat

Mesh:

Substances:

Year:  2017        PMID: 28539449      PMCID: PMC5512246          DOI: 10.1128/JVI.00603-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  HDAC inhibitors in HIV.

Authors:  Fiona Wightman; Paula Ellenberg; Melissa Churchill; Sharon R Lewin
Journal:  Immunol Cell Biol       Date:  2011-11-15       Impact factor: 5.126

2.  Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.

Authors:  Tae-Wook Chun; Danielle Murray; Jesse S Justement; Jana Blazkova; Claire W Hallahan; Olivia Fankuchen; Kathleen Gittens; Erika Benko; Colin Kovacs; Susan Moir; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

3.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Authors:  Nancy M Archin; Rosalie Bateson; Manoj K Tripathy; Amanda M Crooks; Kuo-Hsiung Yang; Noelle P Dahl; Mary F Kearney; Elizabeth M Anderson; John M Coffin; Matthew C Strain; Douglas D Richman; Kevin R Robertson; Angela D Kashuba; Ronald J Bosch; Daria J Hazuda; Joann D Kuruc; Joseph J Eron; David M Margolis
Journal:  J Infect Dis       Date:  2014-03-11       Impact factor: 5.226

Review 4.  Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?

Authors:  Thomas A Rasmussen; Sharon R Lewin
Journal:  Curr Opin HIV AIDS       Date:  2016-07       Impact factor: 4.283

5.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

6.  Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Authors:  Adjoa Smalls-Mantey; Nicole Doria-Rose; Rachel Klein; Andy Patamawenu; Stephen A Migueles; Sung-Youl Ko; Claire W Hallahan; Hing Wong; Bai Liu; Lijing You; Johannes Scheid; John C Kappes; Christina Ochsenbauer; Gary J Nabel; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

7.  Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.

Authors:  Joseph P Casazza; Kathryn A Bowman; Selorm Adzaku; Emily C Smith; Mary E Enama; Robert T Bailer; David A Price; Emma Gostick; Ingelise J Gordon; David R Ambrozak; Martha C Nason; Mario Roederer; Charla A Andrews; Frank M Maldarelli; Ann Wiegand; Mary F Kearney; Deborah Persaud; Carrie Ziemniak; Raphael Gottardo; Julie E Ledgerwood; Barney S Graham; Richard A Koup
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

8.  Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.

Authors:  Vijaya Madhavi; Fernanda E Ana-Sosa-Batiz; Sinthujan Jegaskanda; Rob J Center; Wendy R Winnall; Matthew S Parsons; Jintanat Ananworanich; David A Cooper; Anthony D Kelleher; Denise Hsu; Sarah Pett; Ivan Stratov; Marit Kramski; Stephen J Kent
Journal:  J Infect Dis       Date:  2014-08-28       Impact factor: 5.226

9.  Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus.

Authors:  T M Folks; D Powell; M Lightfoote; S Koenig; A S Fauci; S Benn; A Rabson; D Daugherty; H E Gendelman; M D Hoggan
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

10.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Authors:  Kai Deng; Mihaela Pertea; Anthony Rongvaux; Leyao Wang; Christine M Durand; Gabriel Ghiaur; Jun Lai; Holly L McHugh; Haiping Hao; Hao Zhang; Joseph B Margolick; Cagan Gurer; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Steven G Deeks; Till Strowig; Priti Kumar; Janet D Siliciano; Steven L Salzberg; Richard A Flavell; Liang Shan; Robert F Siliciano
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

View more
  6 in total

1.  Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells.

Authors:  Sai Priya Anand; Jérémie Prévost; Sophie Baril; Jonathan Richard; Halima Medjahed; Jean-Philippe Chapleau; William D Tolbert; Sharon Kirk; Amos B Smith; Bruce D Wines; Stephen J Kent; P Mark Hogarth; Matthew S Parsons; Marzena Pazgier; Andrés Finzi
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.

Authors:  Marina Tuyishime; Carolina Garrido; Shalini Jha; Matt Moeser; Dieter Mielke; Celia LaBranche; David Montefiori; Barton F Haynes; Sarah Joseph; David M Margolis; Guido Ferrari
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

3.  Boosting of Markers of Fcγ Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption.

Authors:  Hugh Billings; Bruce D Wines; Wayne B Dyer; Robert J Center; Halina M Trist; Stephen J Kent; P Mark Hogarth
Journal:  AIDS Res Hum Retroviruses       Date:  2019-08-21       Impact factor: 2.205

Review 4.  What Can Gamma Delta T Cells Contribute to an HIV Cure?

Authors:  Jennifer A Juno; Stephen J Kent
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

5.  Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1.

Authors:  Ashley N Nelson; Maria Dennis; Jesse F Mangold; Katherine Li; Pooja T Saha; Kenneth Cronin; Kaitlyn A Cross; Amit Kumar; Riley J Mangan; George M Shaw; Katharine J Bar; Barton Haynes; Anthony M Moody; S Munir Alam; Justin Pollara; Michael G Hudgens; Koen K A Van Rompay; Kristina De Paris; Sallie R Permar
Journal:  NPJ Vaccines       Date:  2022-07-30       Impact factor: 9.399

Review 6.  Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues.

Authors:  Paul W Denton; Ole S Søgaard; Martin Tolstrup
Journal:  Front Microbiol       Date:  2019-08-21       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.